The rising number of opioid-related deaths in the U.S. has translated into big opportunity for pharma companies making the antidote med naloxone, with drugmakers such as Amphastar Pharmaceuticals getting a sizable boost in revenue amid growing demand for its products. But Amphastar could soon face more competition, as the FDA has granted quick approval for a nasal spray opioid antidote that runs at a lower price than injectable treatments and promises increased benefits for caretakers.
A surge of opioid-related deaths in the U.S. has created an opportunity for pharma companies that make the overdose antidote naloxone.
Amphastar is facing a growing chorus of discontent over its overdose drug naloxone, with U.S. officials urging the company to bring down its high prices for the med. Last week, Rep. Elijah Cummings of Maryland asked his state governor to play hardball with the company to negotiate a deal. Now, presidential hopeful Sen. Bernie Sanders (I-VT) is joining the fray, teaming up with Cummings to pressure all state governments to combat rising naloxone prices.
Amphastar is in hot water with U.S. officials again. After New York and other states put the squeeze on the company to drop the price of its overdose drug, naloxone, Rep. Elijah Cummings of Maryland is urging his state's governor to do the same.
Another state official has jumped on the Amphastar-bashing bandwagon. At a news conference Wednesday, Vermont Gov. Peter Shumlin called out Amphastar for boosting the price of its opioid antidote naloxone 62% over the course of a month.
Police and public safety departments around the country have been stocking up on naloxone from Amphastar Pharmaceuticals and other makers as a way to fight heroin and painkiller overdoses. But with prices for the drug doubling in the last year, some are accusing the small California company of overpricing the overdose drug and are asking for some of their money back.
Momenta Pharmaceuticals really wants the U.S. Supreme Court to weigh its argument against Amphastar's rival version of generic Lovenox. But Amphastar is equally eager to keep the Supreme Court out of the case.
Momenta Pharmaceuticals ($MNTA) has lost its exclusive hold on the generic Lovenox market--at least temporarily. Amphastar, which has been developing its own version of the Sanofi ($SNY)
It's official: Sanofi ($SNY) has discontinued its authorized generic version of the Lovenox blood thinner. Apparently, the company thinks it can make more money selling the branded med only, since
It looks as if Momenta Pharmaceuticals ($MNTA) will keep its share of the market for copycat Lovenox. The U.S.-based drugmaker and its partner Sandoz won an injunction against two potential rivals